New immunotherapy cocktail targets tough liver tumors
NCT ID NCT03680508
First seen Apr 05, 2026 · Last updated May 12, 2026 · Updated 7 times
Summary
This phase II trial tests whether combining two immunotherapy drugs (cobolimab and dostarlimab) can shrink or slow advanced liver cancer that cannot be removed by surgery. About 42 adults with a specific type of liver cancer (hepatocellular carcinoma) and mild-to-moderate cirrhosis are participating. The goal is to see if the drugs help the immune system attack the cancer more effectively.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED ADULT PRIMARY LIVER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Oregon Health & Science University Knight Cancer Institute
Portland, Oregon, 97239, United States
-
University of Hawaii
Honolulu, Hawaii, 96813, United States
Conditions
Explore the condition pages connected to this study.